Eribulin mesylate exerts antitumor effects via CD103-Reference-Cited by-同舟云学术

Eribulin mesylate exerts antitumor effects via CD103

Published:2023-05-27 Issue:1 Volume:12 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Oya Kazumasa¹,Nakamura Yoshiyuki¹,Watanabe Rei²,Tanaka Ryota¹,Ichimura Yuki¹,Kubota Noriko¹,Matsumura Yutaka²,Tahara Hideaki³⁴,Okiyama Naoko⁵,Fujimoto Manabu²,Nomura Toshifumi¹,Fujisawa Yasuhiro¹

Affiliation:

1. The Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

2. The Department of Dermatology, Graduate School of Medicine, Osaka University, Osaka, Japan

3. Project Division of Cancer Biomolecular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

4. Department of Cancer Drug Discovery and Development, Osaka International Cancer Center, Osaka, Japan

5. Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

Funder

Eisai Co., Ltd

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2023.2218782

Reference27 articles.

1. Marine drugs for cancer: surfacing biotechnological innovations from the oceans

2. Multiple modes of action of eribulin mesylate: Emerging data and clinical implications

3. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B;Towle MJ;Cancer Res,2001

4. Antimitotic and non-mitotic effects of eribulin mesilate in soft tissue sarcoma;Kawano S;Anticancer Res,2016

5. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states